Related references
Note: Only part of the references are listed.Biodistribution and Dosimetry Evaluation for a Novel Tau Tracer [18F]-S16 in Healthy Volunteers and Its Application in Assessment of Tau Pathology in Alzheimer's Disease
Ying Wang et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2022)
Synthesis and Evaluation of Fluorine-18 Labeled 2-Phenylquinoxaline Derivatives as Potential Tau Imaging Agents
Kaixiang Zhou et al.
MOLECULAR PHARMACEUTICS (2021)
Functional Abnormality Associated With Tau Deposition in Alzheimer's Disease - A Hybrid Positron Emission Tomography/MRI Study
Liping Fu et al.
FRONTIERS IN AGING NEUROSCIENCE (2021)
Binding of [18F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients
Jolien Schaeverbeke et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Improved quantification of amyloid burden and associated biomarker cut-off points: results from the first amyloid Singaporean cohort with overlapping cerebrovascular disease
Tomotaka Tanaka et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand F-18-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls
Tobey J. Betthauser et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
The Tau Positron-Emission Tomography Tracer AV-1451 Binds With Similar Affinities to Tau Fibrils and Monoamine Oxidases
Celine Vermeiren et al.
MOVEMENT DISORDERS (2018)
[F-18]AV-1451 tau-PET and primary progressive aphasia
Keith A. Josephs et al.
ANNALS OF NEUROLOGY (2018)
Distinct [F-18]THK5351 binding patterns in primary progressive aphasia variants
Jolien Schaeverbeke et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions
Victor L. Villemagne et al.
NATURE REVIEWS NEUROLOGY (2018)
[F-18]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy
Matthias Brendel et al.
FRONTIERS IN AGING NEUROSCIENCE (2018)
Clinical, Anatomical, and Pathological Features in the Three Variants of Primary Progressive Aphasia: A Review
Maxime Montembeault et al.
FRONTIERS IN NEUROLOGY (2018)
In Vivo Comparison of Tau Radioligands 18F-THK-5351 and 18F-THK-5317
Tobey J. Betthauser et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Subcortical 18F-AV-1451 Binding Patterns in Progressive Supranuclear Palsy
Hanna Cho et al.
MOVEMENT DISORDERS (2017)
Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain
Kok Pin Ng et al.
ALZHEIMERS RESEARCH & THERAPY (2017)
Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease
Chenjie Xia et al.
JAMA NEUROLOGY (2017)
18F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study
Daniel R. Schonhaut et al.
ANNALS OF NEUROLOGY (2017)
[F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging
Marta Marquie et al.
ACTA NEUROPATHOLOGICA (2017)
Typical and Atypical Pathology in Primary Progressive Aphasia Variants
Edoardo G. Spinelli et al.
ANNALS OF NEUROLOGY (2017)
Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm
Konstantinos Chiotis et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Tracer Kinetic Analysis of (S)-18F-THK5117 as a PET Tracer for Assessing Tau Pathology
My Jonasson et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Impact of spillover from white matter by partial volume effect on quantification of amyloid deposition with [11C]PiB PET
Keisuke Matsubara et al.
NEUROIMAGE (2016)
An autoradiographic evaluation of AV-1451 Tau PET in dementia
Val J. Lowe et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2016)
Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue
Marta Marquie et al.
ANNALS OF NEUROLOGY (2015)
[18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease
Ryuichi Harada et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Visualization of regional tau deposits using 3H-THK5117 in Alzheimer brain tissue
Laetitia Lemoine et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2015)
Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET
Nobuyuki Okamura et al.
BRAIN (2014)
[18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Chun-Fang Xia et al.
ALZHEIMERS & DEMENTIA (2013)
Classification of primary progressive aphasia and its variants
M. L. Gorno-Tempini et al.
NEUROLOGY (2011)
18F Stilbenes and Styrylpyridines for PET Imaging of Aβ Plaques in Alzheimer's Disease: A Miniperspective
Hank F. Kung et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Consideration of Optimal Time Window for Pittsburgh Compound B PET Summed Uptake Measurements
Rebecca L. McNamee et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Tau exon 10 alternative splicing and tauopathies
Fei Liu et al.
MOLECULAR NEURODEGENERATION (2008)
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry
Heiko Braak et al.
ACTA NEUROPATHOLOGICA (2006)
Astrocytic degeneration relates to the severity of disease in frontotemporal dementia
M Broe et al.
BRAIN (2004)
Diagnosis and management of progressive supranuclear palsy
I Litvan
SEMINARS IN NEUROLOGY (2001)